Sign In
Buy KNSA
$47.85
+0.93 (+1.98%)
At Close: Jun 03, 2026
Kiniksa Announces Commercial Availability of ARCALYST ® (rilonacept) for Recurrent Pericarditis
08:00am, Thursday, 01'st Apr 2021
- ARCALYST is the first and only FDA-approved therapy for recurrent pericarditis – - ARCALYST now available on prescription basis in the U.S. – - Kiniksa One Connect™ program provides ongoing pa
Kiniksa Announces FDA Approval of ARCALYST ® (rilonacept) for Recurrent Pericarditis
04:30pm, Thursday, 18'th Mar 2021
- ARCALYST is the first and only FDA-approved therapy for recurrent pericarditis - - Commercial launch expected in April 2021 - - Kiniksa launches Kiniksa One Connect™ patient support program - - C
Kiniksa Reports Fourth Quarter and Full-Year 2020 Financial Results and Corporate and Pipeline Activity
08:00am, Tuesday, 23'rd Feb 2021
- Strong execution across pipeline of immune-modulating assets throughout 2020 enables multiple milestones in 2021 - - Rilonacept in recurrent pericarditis granted priority review, with PDUFA goal dat
Kiniksa Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference
04:20pm, Monday, 04'th Jan 2021
HAMILTON, Bermuda, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 39th Annual J.P. Morgan Healthcare Conference on Mond
Kiniksa Announces Data from U.S. Investigator-Initiated Study of Mavrilimumab in Severe COVID-19 Pneumonia and Hyperinflammation
08:00am, Tuesday, 22'nd Dec 2020
- Early signal of efficacy with trends toward lower mortality and shorter duration of mechanical ventilation in patients treated with mavrilimumab –
Kiniksa Commences Dosing of Vixarelimab Phase 2b Clinical Trial in Prurigo Nodularis
08:00am, Tuesday, 15'th Dec 2020
– Evaluating vixarelimab across a range of once-monthly dose regimens injected subcutaneously – – Evaluating vixarelimab across a range of once-monthly dose regimens injected subcutaneously –
Kiniksa Announces Preliminary Data from Phase 1 Trial of KPL-404
08:00am, Monday, 30'th Nov 2020
- R eceptor occupancy and TDAR suppression shown through Day 29 at 3 mg/kg intravenous –
Kiniksa Announces U.S. FDA Acceptance of sBLA and Priority Review for Rilonacept in Recurrent Pericarditis
08:00am, Monday, 23'rd Nov 2020
- PDUFA goal date of March 21, 2021 - - Filing based on positive data from RHAPSODY , which achieved its primary and all major secondary endpoints - - Rilonacept BLA for CAPS transferred to Kiniksa
Primary and secondary efficacy endpoints achieved statistical significance; mavrilimumab reduced risk of flare and increased sustained remission Primary and secondary efficacy endpoints achieved stati
Kiniksa Reports Third Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity
07:30am, Thursday, 05'th Nov 2020
HAMILTON, Bermuda, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate immunolo
Kiniksa expects to initiate a dose-ranging Phase 2b clinical trial of vixarelimab in prurigo nodularis in the fourth quarter of 2020 Kiniksa expects to initiate a dose-ranging Phase 2b clinical trial
- Mavrilimumab r educe d t ime - to - f lare and i ncrease d s ustained r emission in Phase 2 giant cell arteritis clinical t rial - - Primary and secondary efficacy endpoints achieved statistical s
Kiniksa Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Conference
12:00pm, Tuesday, 04'th Aug 2020
HAMILTON, Bermuda, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 2020 Wedbush PacGrow Healthcare Conference on Tuesday, Aug
Kiniksa Reports Second Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity
11:30am, Thursday, 30'th Jul 2020
– Rilonacept pivotal Phase 3 trial in recurrent pericarditis met statistical significance for primary and all major secondary efficacy endpoints; sBLA submission expected this year –– Mavrilim
Do Insiders Own Lots Of Shares In Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)?
07:42pm, Tuesday, 28'th Jul 2020
Every investor in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) should be aware of the most powerful shareholder groups...
